Insulet (NASDAQ:PODD) Stock Gets Price Target Increase from Leerink Partners

Insulet (NASDAQ:PODD) had its target price increased by stock analysts at Leerink Partners from $143.00 to $167.00 in a research note issued on Thursday, Benzinga reports. The brokerage presently has a “market perform” rating on the medical instruments supplier’s stock. Leerink Partners‘s target price points to a potential upside of 8.08% from the company’s previous close.

Several other analysts have also recently weighed in on PODD. JPMorgan Chase & Co. cut shares of Insulet from an “overweight” rating to a “neutral” rating and dropped their price target for the company from $275.00 to $152.00 in a research note on Thursday, August 6th. BTIG Research lowered shares of Insulet from a “buy” rating to a “neutral” rating in a research report on Thursday, August 6th. Barclays upgraded Insulet to a “hold” rating in a report on Wednesday, October 7th. UBS Group lowered their price objective on Insulet from $174.00 to $150.00 and set a “neutral” rating for the company in a research report on Thursday, August 6th. Finally, Raymond James Financial reissued an “outperform” rating and set a $180.00 target price on shares of Insulet in a research note on Thursday, August 6th. Thirteen equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Insulet has an average rating of “Hold” and a consensus target price of $190.88.

Insulet Trading Down 6.4%

NASDAQ PODD traded down $10.51 on Thursday, reaching $154.51. 843,811 shares of the company were exchanged, compared to its average volume of 1,395,500. The business’s fifty day moving average price is $141.65 and its 200 day moving average price is $178.00. The stock has a market capitalization of $10.72 billion, a P/E ratio of 28.85, a price-to-earnings-growth ratio of 1.22 and a beta of 1.06. The company has a current ratio of 2.48, a quick ratio of 1.83 and a debt-to-equity ratio of 0.65. Insulet has a fifty-two week low of $126.40 and a fifty-two week high of $354.88.

Insulet (NASDAQ:PODD) last issued its earnings results on Wednesday, November 4th. The medical instruments supplier reported $1.99 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.59 by $0.40. Insulet had a return on equity of 29.29% and a net margin of 12.29%. The company had revenue of $842.00 million during the quarter, compared to analysts’ expectations of $832.63 million. During the same period in the prior year, the business earned $1.24 EPS. The firm’s quarterly revenue was up 19.2% on a year-over-year basis. Analysts forecast that Insulet will post 6.51 earnings per share for the current year.

Institutional Trading of Insulet

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PODD. State of Wyoming increased its holdings in shares of Insulet by 34.6% in the 1st quarter. State of Wyoming now owns 284 shares of the medical instruments supplier’s stock valued at $60,000 after acquiring an additional 73 shares during the period. American Trust boosted its stake in Insulet by 8.6% during the 1st quarter. American Trust now owns 1,180 shares of the medical instruments supplier’s stock worth $248,000 after purchasing an additional 93 shares during the period. Basecamp Wealth Advisors LLC boosted its stake in Insulet by 48.3% during the 1st quarter. Basecamp Wealth Advisors LLC now owns 313 shares of the medical instruments supplier’s stock worth $66,000 after purchasing an additional 102 shares during the period. Elevation Wealth Partners LLC grew its position in Insulet by 115.6% during the 3rd quarter. Elevation Wealth Partners LLC now owns 194 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 104 shares during the last quarter. Finally, Pinnacle Associates Ltd. grew its position in Insulet by 6.1% during the 3rd quarter. Pinnacle Associates Ltd. now owns 1,855 shares of the medical instruments supplier’s stock worth $242,000 after purchasing an additional 107 shares during the last quarter.

Key Insulet News

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet reported Q3 adjusted EPS of $1.99 versus $1.59 expected and revenue of $842 million versus $832.6 million expected. Revenue grew 19.2% year over year, and reports noted margin expansion and a stronger 2026 outlook, though the full-year EPS outlook was maintained. Insulet Q3 Earnings and Revenues Surpass Estimates
• Positive Sentiment: The company announced a $1 billion share repurchase program, which may support per-share value and signal confidence in its business outlook. Insulet Announces $1 Billion Equity Buyback
• Positive Sentiment: Several firms raised their price targets: Bernstein to $200 with an Outperform rating, RBC to $180 with Outperform, and Wells Fargo to $172. RBC Raises Insulet Price Target
• Neutral Sentiment: UBS also lifted its target, to $171 from $150, but kept a Neutral rating—recognizing improved prospects without signaling a stronger recommendation. UBS Adjusts Insulet Price Target
• Negative Sentiment: Management expects slower growth in 2027 and anticipates rivals taking some share from its Omnipod product. Those concerns may temper enthusiasm after the earnings beat and help explain why the stock is lower in Thursday trading. CEO Sees Slower Growth and Competition

About Insulet

Insulet Corporation is a medical device company that develops, manufactures and sells wearable, tubeless insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.

The company’s primary product platform is Omnipod, which includes the disposable, wearable Pod and a handheld controller or compatible smartphone-based application. Omnipod products include the Omnipod DASH system and the Omnipod 5 Automated Insulin Delivery System, which is designed to integrate with compatible continuous glucose monitoring technology to help automate insulin delivery.